BioSpace News Archive

Company to feature latest milestones and technology advancements in vascular robotics at SCAI 2019

Cresco Labs Inc., one of the largest vertically integrated multistate cannabis operators in the United States, will report its financial results for the first quarter ended March 31, 2019 on Wednesday, May 29, 2019 after the market closes.

Brent Zettl, the President and CEO of ZYUS Life Sciences Inc., received the Startup Canada Entrepreneur of the Year Award for the Prairies region in Edmonton, Alberta sponsored by Scotiabank.

Allergan plc (NYSE: AGN) today announced the expansion of the PLEDGE program with a fifth study now evaluating relamorelin, an investigational, ghrelin agonist being studied for the treatment of diabetic gastroparesis (DG).

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), today provided an update on its application for FDA clearance and addressed a recent anonymous article published on SeekingAlpha.com.

Cardax, Inc. (OTCQB:CDXI) announced results for the quarter ended March 31, 2019, in its Quarterly Report on Form 10-Q filed May 15, 2019 with the SEC.

Mylan N.V. (NASDAQ: MYL) yesterday presented at the Bank of America Merrill Lynch Healthcare Conference, where the company announced that it will host an Investor Day on July 31, 2019 in New York City.

Takeda Pharmaceuticals, U.S.A., Inc. (“Takeda”), announced today that the U.S. Food and Drug Administration (FDA) approved extending the indication of GATTEX® (teduglutide) for injection to pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who need additional nutrition or fluids from intravenous (IV) feeding (parenteral support).1

pMD, the innovation leader in health care technology, is pleased to announce that it has again been honored as one of the best places to work across the nation by both Modern Healthcare and Inc. Magazine, marking three consecutive years on both lists.

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has initiated sites for its ELEVATE UC Phase 3 global program to evaluate etrasimod 2 mg in subjects with moderately to severely active ulcerative colitis (UC).